The University of Colorado Cancer Center (UCCC) requests continued support for participation in the Southwest Oncology Group (SWOG) as a member institution. The UCCC mission is the reduction of cancer incidence and mortality through laboratory and clinical research. Participation in SWOG has been an integral part of this mission. Investigators from the UCCC continue to contribute to the administrative, educational and scientific functions of SWOG. Drs. Scott Bearman (Principal Investigator), E. David Crawford, and Laurie Gaspar sit on the Board of Governors, SWOG's executive committee. UCCC SWOG members chair the Genitourinary (E.D. Crawford) and Lung Pathobiology (Wilbur Franklin) Committees. Dr. Scott Lucia serves as the director of the Diagnostic Center for the Prostate Cancer Prevention Trial (PCPT). Dr. Lucia is also a member of the steering committees for PCPT and Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Michele Basche was selected as a SWOG Young Investigator in 2002. UCCC members are coordinators or co-coordinators of 11% of active SWOG protocols activated during the 1997-2002 grant period. In addition, institutional pilot studies conducted at the UCCC have been brought to the Group in the form of prospective randomized trials and groupwide Phase II studies. UCCC investigators make important contributions to the Blood and Marrow Transplantation, Breast, Lung, Radiation Therapy and GU Committees. New faculty members are expected to increase participation further, particularly in the Gastrointestinal (S. Gail Eckhardt and Michele Basche) and Lymphoma (John Sweetenham) Committees. We are proud of our contributions to the Southwest Oncology Group and are committed to its mission. We expect our Southwest Oncology Group activities to increase in the next grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA042777-19
Application #
7049457
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-01-21
Project End
2006-12-31
Budget Start
2006-04-13
Budget End
2006-12-31
Support Year
19
Fiscal Year
2006
Total Cost
$164,202
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33

Showing the most recent 10 out of 222 publications